¥È¥Ã¥× º¹Ê¬ °ìÍ÷ ¥½¡¼¥¹ ¸¡º÷ ¥Ø¥ë¥× PDF RSS ¥í¥°¥¤¥ó

¥¤¥Ù¥ë¥á¥¯¥Á¥ó

¥¤¥Ù¥ë¥á¥¯¥Á¥ó½ªÎ»¤Î¤ªÃΤ餻

´óÀ¸Ã¸¶°ø¤Ç¼ºÌÀ¤Ê¤É¤¬°ú¤­µ¯¤³¤µ¤ì¤ë´¶À÷¾É¤ÎÆÃ¸úÌô¡Ö¥¤¥Ù¥ë¥á¥¯¥Á¥ó¡×¤Ë¤Ä¤¤¤Æ¡¢¿··¿¥³¥í¥Ê´µ¼Ô¤ËÅêÍ¿¤·¤Æ¤â¸ú²Ì¤¬¤ß¤é¤ì¤Ê¤«¤Ã¤¿¤È¤¹¤ë·ë²Ì¤ò¡¢¼£¸³¤ò¿Ê¤á¤Æ¤¤¤¿ËÌΤÂç³ØÉ±¡¤Ê¤É¤Î¥°¥ë¡¼¥×¤¬È¯É½¤·¤Þ¤·¤¿¡£

¡¡

¼£¸³¤ÏËÌΤÂç³ØÉ±¡¤Ê¤É¤Î¥°¥ë¡¼¥×¤¬¹Ô¤¤¡¢º£·î22Æü¡¢³¤³°¤Î°å³Ø»¨»ï¤Ë·ë²Ì¤ò¤Þ¤È¤á¤¿ÏÀʸ¤òȯɽ¤·¤Þ¤·¤¿¡£

¡¡

¤½¤ì¤Ë¤è¤ê¤Þ¤¹¤È¡¢¼£¸³¤Ï2020ǯ8·î¤«¤é¤ª¤È¤È¤·10·î¤Þ¤Ç¿··¿¥³¥í¥Ê¤Ë´¶À÷¤·¤¿20ºÐ°Ê¾å¤ÎÃæÅù¾É¤Þ¤Ç¤Î´µ¼Ô248¿Í¤òÂоݤ˹Ԥï¤ì¡¢¥¤¥Ù¥ë¥á¥¯¥Á¥ó¤ò1²óÉþÍѤ¹¤ë¥°¥ë¡¼¥×¤Èµ¶¤ÎÌô¤òÉþÍѤ¹¤ë¥°¥ë¡¼¥×¤Ëʬ¤±¤Æ¡¢´µ¼Ô¤â°å»Õ¤â¤É¤Á¤é¤¬ÅêÍ¿¤µ¤ì¤Æ¤¤¤ë¤«Ê¬¤«¤é¤Ê¤¤ÊýË¡¤ÇPCR¸¡ºº¤Ç±¢À­¤È¤Ê¤ë¤Þ¤Ç¤Î´ü´Ö¤òÈæ³Ó¤·¤Þ¤·¤¿¡£

¡¡

¤½¤Î·ë²Ì¡¢¤¤¤º¤ì¤Î¥°¥ë¡¼¥×¤Ç¤â14ÆüÁ°¸å¤Ç±¢À­¤È¤Ê¤ê¡¢±¢À­¤È¤Ê¤ë¤Þ¤Ç¤Î»þ´Ö¤Ëº¹¤Ï¤Ê¤¯¡¢¥¤¥Ù¥ë¥á¥¯¥Á¥ó¤ÎÅêÍ¿¤Ç»þ´Ö¤òû½Ì¤¹¤ë¸ú²Ì¤Ï¤Ê¤«¤Ã¤¿¤È·ëÏÀ¤Å¤±¤Æ¤¤¤Þ¤¹¡£

Ëܻ¤Ï¡¢·Ú¾É¤Î¿··¿¥³¥í¥Ê¥¦¥¤¥ë¥¹´¶À÷¾É¡ÊCOVID-19¡Ë´µ¼Ô1,030Îã¤òÂоݤȤ·¤Æ¼Â»Ü¤·¤¿¹ñºÝ¶¦Æ±¡¢Â¿»ÜÀß¶¦Æ±¡¢¥×¥é¥»¥ÜÂоȡ¢Ìµºî°Ù²½¡¢Æó½ÅÌÕ¸¡¡¢Ê¹Է²´ÖÈæ³Ó»î¸³¤Ç¤¹¡£Ëܺޤϡ¢¼çÍ×ɾ²Á¹àÌܤǤ¢¤ë¼£¸³Ìô¤ÎÅêÍ¿³«»Ï¤«¤é168»þ´Ö¤Þ¤Ç¤ÎÎ×¾²¾É¾õ¤¬²þÁ±·¹¸þ¤Ë»ê¤ë¤Þ¤Ç¤Î»þ´Ö¤ò¥×¥é¥»¥Ü¤ÈÈæ³Ó¤·¤¿·ë²Ì¡¢°ÂÁ´À­¤Ï³Îǧ¤µ¤ì¤Þ¤·¤¿¡£¤Þ¤¿¡¢»àË´Îã¤Ï¤Ê¤¯¡¢½Å¾É²½Îã¤â¤Û¤È¤ó¤Éǧ¤á¤é¤ì¤Þ¤»¤ó¤Ç¤·¤¿¡£¤·¤«¤·¤Ê¤¬¤é¡¢¥ª¥ß¥¯¥í¥ó³ô¤¬¼çή¤È¹Í¤¨¤é¤ì¤ëº£²ó¤ÎÂоݴµ¼Ô¤Ë¤ª¤¤¤Æ¤Ï¡¢Ëܺޤª¤è¤Ó¥×¥é¥»¥Ü¤È¤â¤ËÅêÍ¿³«»Ï4ÆüÁ°¸å¤Ç¾É¾õ¤Î·Ú¾É²½¤¬Ç§¤á¤é¤ì¤Þ¤·¤¿¤¬¡¢ËܺޤÎÍ­¸úÀ­¤ò¸«½Ð¤¹¤³¤È¤¬¤Ç¤­¤Þ¤»¤ó¤Ç¤·¤¿¡£¶½Ï¤ϰú¤­Â³¤­¡¢ºÙÉô¤ËÅϤêÍÍ¡¹¤Ê³ÑÅÙ¤«¤éËܻ·ë²Ì¤Î¥Ç¡¼¥¿²òÀϤò¿Ê¤á¡¢ËܺޤβÄǽÀ­¤Ë¤Ä¤¤¤Æ¤µ¤é¤Ë³Îǧ¤·¤Æ¤Þ¤¤¤ê¤Þ¤¹¡£¤Ê¤ª¡¢Ëܻ·ë²Ì¤Î¾ÜºÙ¤Ë¤Ä¤­¤Þ¤·¤Æ¤Ï¡¢³Ø²ñ¤Þ¤¿¤ÏÏÀʸ¤Ë¤Æ¸øÉ½¤¹¤ëͽÄê¤Ç¤´¤¶¤¤¤Þ¤¹¡£

¼£¸³¤Ïµîǯ11·î¤«¤éÀè·î¤Þ¤Ç12ºÐ°Ê¾å¤Î·Ú¾É¤Î¥³¥í¥Ê´µ¼Ô1030¿Í¤òÂоݤ˹Ԥï¤ì¡¢°ìÆü1²ó¡¢3Æü´Ö¡¢¥¤¥Ù¥ë¥á¥¯¥Á¥ó¤òÉþÍѤ¹¤ë¥°¥ë¡¼¥×¤Èµ¶¤ÎÌô¤òÉþÍѤ¹¤ë¥°¥ë¡¼¥×¤Ëʬ¤±¤Æ¡¢´µ¼Ô¤â°å»Õ¤â¤É¤Á¤é¤¬ÅêÍ¿¤µ¤ì¤Æ¤¤¤ë¤«Ê¬¤«¤é¤Ê¤¤ÊýË¡¤ÇÈæ³Ó¤·¤¿¤È¤¤¤¦¤³¤È¤Ç¤¹¡£

¡¡

¤½¤Î·ë²Ì¡¢¤¤¤º¤ì¤Î¥°¥ë¡¼¥×¤Ç¤âÅêÍ¿¤«¤é4ÆüÁ°¸å¤ÇȯǮ¤ä¤Î¤É¤ÎÄˤߤʤɤξɾõ¤¬¼£¤Þ¤ê¡¢Ìô¤Ë¤è¤Ã¤Æ²þÁ±¤·¤¿¤È¤¤¤¦Í­¸úÀ­¤¬¸«¤¤¤À¤»¤Ê¤«¤Ã¤¿¤È¤¤¤¦¤³¤È¤Ç¡¢²ñ¼Ò¤Ï¿··¿¥³¥í¥Ê¤Î¼£ÎÅÌô¤È¤·¤Æ¤Î¾µÇ§¿½ÀÁ¤òÃÇǰ¤¹¤ë¤Èȯɽ¤·¤Þ¤·¤¿¡£

¡¡

¥¤¥Ù¥ë¥á¥¯¥Á¥ó¤Ï¡¢¥Î¡¼¥Ù¥ëÀ¸Íý³Ø¡¦°å³Ø¾Þ¤ò¼õ¾Þ¤·¤¿ËÌΤÂç³Ø¤ÎÂç¼ÃÒÆÃÊ̱ÉÍÀ¶µ¼ø¤Î¸¦µæ¤ò¸µ¤Ë³«È¯¤µ¤ì¤¿¡¢´óÀ¸Ãî¤Ë¤è¤Ã¤Æ¼ºÌÀ¤ä¥ê¥ó¥Ñ´É¤Î¼ð¤ì¤¬°ú¤­µ¯¤³¤µ¤ì¤ëɵ¤¤ÎÆÃ¸úÌô¤Ç¡¢¿··¿¥³¥í¥Ê¤Ø¤Î¸ú²Ì¤¬¤¢¤ë¤«³Æ¹ñ¤Ç¸¦µæ¤¬¿Ê¤á¤é¤ì¤Þ¤·¤¿¤¬¡¢¤³¤È¤·3·î¡¢¥Ö¥é¥¸¥ë¤Ê¤É¤Î¸¦µæ¥°¥ë¡¼¥×¤¬Æþ±¡¤Ë»ê¤ë¥ê¥¹¥¯¤ò²¼¤²¤ë¤Ê¤É¤Î¸ú²Ì¤Ï¤Ê¤«¤Ã¤¿¤È¤¹¤ëÎ×¾²»î¸³¤Î·ë²Ì¤òȯɽ¤·¤Æ¤¤¤Þ¤·¤¿¡£

¡¡

»°ÎØË§¹°¼ÒĹ¤Ï¡ÖÁ´¼Òµó¤²¤Æ¼£¸³¤ËÎפó¤Ç¤­¤¿¤¬¡¢¤³¤Î·ë²Ì¤Ç¤Ï¾µÇ§¿½ÀÁ¤ò¹Í¤¨¤ë¤³¤È¤Ï¤Ç¤­¤Ê¤¤¡£·ë²Ì¤ò¼õ¤±Æþ¤ì¤¿¤¤¡×¤È½Ò¤Ù¤Þ¤·¤¿¡£

ÏÀʸ´ØÏ¢

¥¤¥Ù¥ë¥á¥¯¥Á¥óÎ×¾²»î¸³ ¿··¿¥³¥í¥Ê¤ÎÆþ±¡Í½Ëɸú²Ìǧ¤á¤é¤ì¤º¡¡

2022ǯ3·î31Æü 16»þ42ʬ¡¢NHK

Î×¾²»î¸³¤Î·ë²Ì¤Ï¡¢¥Ö¥é¥¸¥ë¤ÎÊ£¿ô¤ÎÂç³Ø¤Ê¤É¤Î¸¦µæ¥°¥ë¡¼¥×¤¬¡¢¹ñºÝŪ¤Ê°å³Ø»¨»ï¡Ö¥Ë¥å¡¼¡¦¥¤¥ó¥°¥é¥ó¥É¡¦¥¸¥ã¡¼¥Ê¥ë¡¦¥ª¥Ö¡¦¥á¥Ç¥£¥·¥ó¡×¤Ëȯɽ¤·¤Þ¤·¤¿¡£

¸¦µæ¥°¥ë¡¼¥×¤Ï¡¢µîǯ3·î¤«¤é8·î¤Ë¤«¤±¤Æ¡¢ÈîËþ¤äÅüǢɡ¢¹â·ì°µ¤Ê¤É¡¢¿··¿¥³¥í¥Ê¤Î½Å¾É²½¥ê¥¹¥¯¤¬¤¢¤ë18ºÐ°Ê¾å¤Î´µ¼Ô1358¿Í¤Ë¤Ä¤¤¤Æ¡¢È¯¾É¤«¤é7Æü°ÊÆâ¤Ë¡Ö¥¤¥Ù¥ë¥á¥¯¥Á¥ó¡×¤ò°ìÆü¤Ë1²ó¡¢3Æü´Ö¡¢ÉþÍѤ¹¤ë¥°¥ë¡¼¥×¤Èµ¶¤ÎÌô¤òÉþÍѤ¹¤ë¥°¥ë¡¼¥×¤Ëʬ¤±¤Æ·Ð²á¤òÄ´¤Ù¤Þ¤·¤¿¡£

¤½¤Î·ë²Ì¡¢4½µ´Ö°ÊÆâ¤ËÆþ±¡¤¹¤ë¤«µßµÞ³°Íè¤ò¼õ¿Ç¤·¤¿´µ¼Ô¤Ï¡Ö¥¤¥Ù¥ë¥á¥¯¥Á¥ó¡×¤òÉþÍѤ·¤¿¥°¥ë¡¼¥×¤Ç14.7¡ó¡¢µ¶¤ÎÌô¤Î¥°¥ë¡¼¥×¤Ç¤Ï16.3¡ó¤Ç¡¢Åý·×³ØÅª¤ËÍ­°Õ¤Êº¹¤Ï¸«¤é¤ì¤Ê¤«¤Ã¤¿¤È¤¤¤¦¤³¤È¤Ç¤¹¡£

¤Þ¤¿¡¢È¯¾É¤«¤é7ÆüÌܤǤÎÂÎÆâ¤Î¥¦¥¤¥ë¥¹Î̤θº¾¯¤ä²óÉü¤¹¤ë¤Þ¤Ç¤Î´ü´Ö¡¢¤½¤ì¤Ë»àË´¤¹¤ë¥ê¥¹¥¯¤Ë¤Ä¤¤¤Æ¤âº¹¤Ï¸«¤é¤ì¤Ê¤«¤Ã¤¿¤È¤·¤Æ¤¤¤Þ¤¹¡£

  • Effect of Early Treatment with Ivermectin among Patients with Covid-19¡¡Gilmar Reis, Eduardo A.S.M. Silva, Daniela C.M. Silva, Lehana Thabane, Aline C. Milagres, Thiago S. Ferreira, Castilho V.Q. dos Santos, Vitoria H.S. Campos, Ana M.R. Nogueira, Ana P.F.G. de Almeida, Eduardo D. Callegari, Adhemar D.F. Neto, et al., The new england journal of medicine

¥¤¥Ù¥ë¥á¥¯¥Á¥ó¡¢RCT¤ÇÍ­¸úÀ­¼¨¤»¤º¡¡

¡ÊÊ¿»³Ìмù¡¢Medical Tribune¡á»þ»ö¡Ë2022/02/24 11:59

¿··¿¥³¥í¥Ê¥¦¥¤¥ë¥¹´¶À÷¾É¡ÊCOVID-19¡Ë¤Ø¤ÎÍ­¸úÀ­¤Ë¤Ä¤¤¤ÆµÄÏÀ¤¬Â³¤¤¤Æ¤¤¤ë¹³´óÀ¸ÃîÌô¥¤¥Ù¥ë¥á¥¯¥Á¥ó¤Ë¡¢¿·¤¿¤Ê¥é¥ó¥À¥à²½Èæ³Ó»î¸³¡ÊRCT¡Ë¤Î·ë²Ì¤¬¼¨¤µ¤ì¤¿¡£¥Þ¥ì¡¼¥·¥¢¡¦Raja Permaisuri Bainun Hospital¤ÎSteven Chee Loon Lim»á¤é¤ÏJAMA Intern Med¡Ê2022ǯ2·î18Æü¥ª¥ó¥é¥¤¥óÈǡˤǡ¢¹â¥ê¥¹¥¯¤ÎCOVID-19´µ¼Ô¤òÂоݤ˥¤¥Ù¥ë¥á¥¯¥Á¥ó¤ÎÍ­¸úÀ­¤ò¸¡Æ¤¤·¤¿¤È¤³¤í¡¢Æ±Ìô¤Ë½Å¾É²½¤òËɤ°¸ú²Ì¤Ïǧ¤á¤é¤ì¤Ê¤«¤Ã¤¿¤ÈÊó¹ð¤·¤¿¡£

¥¤¥Ù¥ë¥á¥¯¥Á¥ó»ÈÍѤÎÍ­³²»ö¾Ý¤òÊó¹ð ¥Ñ¥ó¥Ç¥ß¥Ã¥¯¸å¡¢Êƹñ¤Ç»ÈÍÑÎ㤬µÞÁý¡¡

2021ǯ10·î22Æü 17:28, Medical Tribune

¡¡¹³´óÀ¸ÃîÌô¥¤¥Ù¥ë¥á¥¯¥Á¥ó¤Ë¿··¿¥³¥í¥Ê¥¦¥¤¥ë¥¹´¶À÷¾É¡ÊCOVID-19¡Ë¤ËÂФ¹¤ë¼£ÎŸú²Ì¤ò´üÂÔ¤¹¤ë¸þ¤­¤¬¤¢¤ë¤â¤Î¤Î¡¢¥é¥ó¥À¥à²½Èæ³Ó»î¸³¡ÊRCT¡Ë¤ÇÍ­¸úÀ­¤Ï¼¨¤µ¤ì¤Æ¤¤¤Ê¤¤¡£¤·¤«¤·¡¢Êƹñ¤Ç¤ÏCOVID-19¥Ñ¥ó¥Ç¥ß¥Ã¥¯¸å¤Ë½èÊý¤¬µÞÁý¤·¤Æ¤ª¤ê¡¢ÊƼÀÉÂÂкö¥»¥ó¥¿¡¼¡ÊCDC¡Ë¤¬¥¤¥Ù¥ë¥á¥¯¥Á¥ó¤Î»ÈÍѤËÃí°Õ¤ò´­µ¯¤¹¤ë»öÂ֤ȤʤäƤ¤¤ë¡£ÊÆ¡¦Oregon Health and Science University¤ÎCourtney Temple»á¤é¤ÏNew Engl J Med¡Ê2021ǯ10·î21Æü¥ª¥ó¥é¥¤¥óÈǡˤǡ¢Æ±¹ñ¥ª¥ì¥´¥ó½£¤ÎÅÅÏÃÁêÃÌ¥»¥ó¥¿¡¼¤Ë´ó¤»¤é¤ì¤¿¥¤¥Ù¥ë¥á¥¯¥Á¥ó»ÈÍÑÎã¤Ë¤ª¤±¤ëÍ­³²»ö¾Ý¤Î»öÎã¤ò¾Ò²ð¡£21ÎãÃæ6Î㤬Æþ±¡¤·¤¿¤ÈÊó¹ð¤·¤¿¡£

High-dose ivermectin for early treatment of COVID-19 (COVER study): a randomised, double-blind, multicentre, phase II, dose-finding, proof-of-concept clinical trial

Dora Buonfrate, Fabio Chesini, Davide Martini, Maria Carla Roncaglioni, Maria Luisa Ojeda Fernandez, Maria Francesca Alvisi, Irene De Simone, Eliana Rulli, Alessandro Nobili, Giacomo Casalini, Spinello Antinori, Marco Gobbi, Caterina Campoli, Michela Deiana, Elena Pomari, Gianluigi Lunardi, Roberto Tessari , Zeno Bisoffi, Int J Antimicrob Agents. 2022 Feb;59(2):106516.

¥¤¥Ù¥ë¥á¥¯¥Á¥ó¤Ï¹âÍÑÎ̤Ǥâ°ÂÁ´¤À¤¬¡¢¥¦¥¤¥ë¥¹Î̤ò¸º¤é¤¹¸ú²Ì¤Ï¤Ê¤«¤Ã¤¿¡¢¤È¤¤¤¦·ëÏÀ¡£

Pharmacometrics of high dose ivermectin in early COVID-19: an open label, randomized, controlled adaptive platform trial (PLATCOV)¡¡

William HK Schilling et al., https://doi.org/10.7554/eLife.83201

¹âÍÑÎ̤Υ¤¥Ù¥ë¥á¥¯¥Á¥ó¤Ï¡¢COVID-19¤Î½é´ü¾É¾õ¤ËÂФ·¤Æ¡¢Â¬Äê²Äǽ¤Ê¹³¥¦¥¤¥ë¥¹³èÀ­¤ò¼¨¤µ¤Ê¤«¤Ã¤¿¡£

¥Ë¥å¡¼¥¹

¡Ö¸í²ò¤ò¾·¤¯¸«½Ð¤·¤Î¥Ä¥¤¡¼¥È¤òºï½ü¤¹¤ë¡£À¤³¦ÊÝ·òµ¡´Ø¡ÊWHO¡Ë¤Ï»ÈÍѤˤĤ¤¤Æ·Ù¹ð¤·¤Æ¤¤¤ë¡×¡£¥í¥¤¥¿¡¼ÄÌ¿®¤Ï1·îËö¡¢¹³´óÀ¸ÃîÌô¡Ö¥¤¥Ù¥ë¥á¥¯¥Á¥ó¡×¤Ë´Ø¤¹¤ëȯ¿®¤òSNS¡Ê¥Í¥Ã¥È¸òή¥µ¡¼¥Ó¥¹¡Ë¾å¤ÇÄûÀµ¤·¤¿¡£

¡¡

¡¡È¯Ã¼¤Ï¡¢Ì¾¸Å²°»Ô¤ÎÀ½Ìô²ñ¼Ò¡Ö¶½Ï¡פ¬¸øÉ½¤·¤¿¡Ö¥¤¥Ù¥ë¥á¥¯¥Á¥ó¤Î¡Ø¥ª¥ß¥¯¥í¥ó³ô¡Ù¤Ø¤Î¹³¥¦¥¤¥ë¥¹¸ú²Ì¤ò³Îǧ¡×¤ÈÂꤷ¤¿¥×¥ì¥¹¥ê¥ê¡¼¥¹¤À¡£¤¢¤¯¤Þ¤Ç»î¸³´ÉÆâ¤ÎºÙ˦¼Â¸³¤Î·ë²Ì¤Ë¤¹¤®¤º¡¢¼ÂºÝ¤Ë´µ¼Ô¤ËÅêÍ¿¤·¤Æ¸¡¾Ú¤·¤¿Î×¾²»î¸³¤Î·ë²Ì¤Ç¤Ï¤Ê¤«¤Ã¤¿¤¬¡¢¥í¥¤¥¿¡¼¤¬Åê¹Æ¤·¤¿¡ÖÎ×¾²»î¸³¤Ç¥ª¥ß¥¯¥í¥ó³ô¤Ø¤ÎÍ­¸úÀ­¤ò³Îǧ¡×¤È¤Î¥Ä¥¤¡¼¥È¤Ï½Ö¤¯´Ö¤Ë³È»¶¤·¤¿¡£

·×26·ï¤Î¸¦µæ¤Î¤¦¤Á5·ï¤Ç¤Ï¡¢¥Ç¡¼¥¿¤¬µ¶Â¤¤µ¤ì¤¿²ÄǽÀ­¤¬¤¢¤Ã¤¿¡£Î㤨¤Ð¡¢»ö¼Â¾åÉÔ²Äǽ¤Ê¿ôÃͤ¬´Þ¤Þ¤ì¤Æ¤¤¤¿¤ê¡¢Æ±¤¸´µ¼Ô¤Î¥Ç¡¼¥¿¤¬Ê£¿ô²ó»ÈÍѤµ¤ì¤ë¤Ê¤É¤·¤Æ¤¤¤¿¡£

¡¡

¤µ¤é¤ËÊ̤Î5·ï¤Ç¤Ï¡¢¿ôÃͤΤĤ¸¤Ä¤Þ¤¬¹ç¤ï¤Ê¤«¤Ã¤¿¤ê¡¢¥Ñ¡¼¥»¥ó¥Æ¡¼¥¸¤Î»»½Ð¤Ë¸í¤ê¤¬¤¢¤Ã¤¿¤Û¤«¡¢Ãϰè¤Î°åÎŵ¡´Ø¤¬¼£¸³¤Î¼Â»Ü¤òǧ¼±¤·¤Æ¤¤¤Ê¤¤¤Ê¤É¡¢½ÅÂç¤ÊÌäÂ꤬¸«¤Ä¤«¤Ã¤¿¡£

¡¡

¤³¤¦¤·¤¿¼£¸³¤ÎÉÔÈ÷¤Ë²Ã¤¨¡¢¤³¤ì¤é¤Î¸¦µæ¤ÎÃø¼Ô14¿Í¤ÏÆÈΩĴºº¥Á¡¼¥à¤Ë¥Ç¡¼¥¿¤òÊÖÁ÷¤·¤Ê¤«¤Ã¤¿¡£¤³¤Î¤³¤È¤«¤é¡¢Ä´ºº¥Á¡¼¥à¤Î²Ê³Ø¼Ô¤¿¤Á¤Ï¡¢ÉÔÀµ¹Ô°Ù¤¬¤¢¤Ã¤¿²ÄǽÀ­¤¬¤¢¤ë¤È»ØÅ¦¤·¤Æ¤¤¤ë¡£

¡¡

Ä´ºº¥Á¡¼¥à¤¬Ä´¤Ù¤¿¸¦µæÏÀʸ¤Î¥µ¥ó¥×¥ë¤Ë¤Ï¡¢À¤³¦³Æ¹ñ¤Î¼Á¤Î¹â¤¤¸¦µæ¤â´Þ¤Þ¤ì¤Æ¤¤¤¿¡£¤·¤«¤·Â礭¤ÊÌäÂê¤Ï¡¢¥¤¥Ù¥ë¥á¥¯¥Á¥ó¤Î¸ú²Ì¤òÂ礭¤¯¤¦¤¿¤¦¸¦µæ¤Ë¤¢¤Ã¤¿¡£¼ÂºÝ¡¢¥¤¥Ù¥ë¥á¥¯¥Á¥ó¤Çµß¤ï¤ì¤¿¤È¤µ¤ì¤ëÌ¿¤ä´¶À÷¤Î¿ô¤¬Â礭¤¤¤Û¤É¡¢ÙÔ¤¤ä¸¦µæ·ë²Ì¤¬Ìµ¸ú¤Ê¤Î¤Ç¤Ï¤Ê¤¤¤«¤È¤¤¤¦·üǰ¤¬Â礭¤¤¤³¤È¤¬¤ï¤«¤Ã¤¿¤È¤·¤Æ¤¤¤ë¡£

¤³¤³¤ÇÌäÂê¤Ë¤µ¤ì¤Æ¤¤¤ë¤Î¤Ï°Ê²¼¤Î¥×¥ì¥×¥ê¥ó¥È¡£¤½¤â¤½¤âººÆÉ¤ò¤Þ¤ÀÄ̤äƤ¤¤Ê¤¤¥×¥ì¥×¥ê¥ó¥È¡ÊÏÀʸ¤Ë¤Ê¤ëÁ°¤ÎÃʳ¬¡Ë¤òº¬µò¤È¤·¤Æ°úÍѤ¹¤ë¤³¤È¤ËÂ礭¤ÊÌäÂ꤬¤¢¤ë¡£

Research Square¤Ë¤è¤ë¤È¡¢·üǰ¤¬É½ÌÀ¤µ¤ì¤¿¤³¤È¤Ë¤è¤ê2021ǯ7·î14Æü¤Ë¤³¤Î¥×¥ì¥×¥ê¥ó¥È¤Ïű²ó¤µ¤ì¤Æ¤ª¤ê¡¢2021ǯ7·î19Æü¸½ºßÀµ¼°¤ËÄ´ººÃæ¤È¤Î¤³¤È¡£Jack Lawrence¤È¤¤¤¦¿Íʪ¤¬¤³¤ÎÏÀʸ¤ÎÌäÂêÅÀ¤ò»ØÅ¦¤·¤Æ¤ª¤ê¡¢Èà¤Î¶¨ÎϼÔNick Brown»á¤¬°Ê²¼¤Î¥Ö¥í¥°¤Ë¤½¤ÎÅ¿Ëö¤ò¤Þ¤È¤á¤Æ¤¤¤ë¡£

¤³¤Á¤é¤âElgazzar¤é¤Î¥×¥ì¥×¥ê¥ó¥È¤Ë´Ø¤¹¤ëµ­»ö¡£

ÊÛ¸î»Î¥É¥Ã¥È¥³¥à¤Ê¤Î¤Ç¡¢Ë¡Î§¾å¤ÎÏäΤߡ£

¡Ö¸Ä¿ÍÍ¢Æþ¤ò¤·¤¿¥¤¥Ù¥ë¥á¥¯¥Á¥ó¤ò¼þ°Ï¤ËÇۤ뤳¤È¤ÏÌôµ¡Ë¡¤Ç¶Ø»ß¤µ¤ì¤Æ¤¤¤Þ¤¹¡£¤â¤È¤â¤È¼«Ê¬¼«¿È¤Ç»ÈÍѤ¹¤ë¾ì¹ç¤Ë¸Â¤Ã¤ÆÌ¤¾µÇ§°åÌôÉʤò¸Ä¿ÍÍ¢Æþ¤¹¤ë¤³¤È¤¬¤Ç¤­¤ëÍýͳ¤Ï¡¢³°¹ñ¤Ç¼õ¤±¤¿Ìôʪ¼£ÎŤò·Ñ³¤·¤¿¤ê¡¢³¤³°¤«¤é¤Îι¹Ô¼Ô¤¬¾ïÈ÷Ìô¤È¤·¤Æ·È¹Ô¤¹¤ë¾ì¹ç¤Ø¤ÎÇÛθ¤Ë¤¢¤ê¤Þ¤¹¡£¤½¤Î¤¿¤á¡¢¸Ä¿ÍÍ¢Æþ¤·¤¿¥¤¥Ù¥ë¥á¥¯¥Á¥ó¤òÇÛ¤ë¤è¤¦¤Ê¤³¤È¤ÏÀäÂФˤ·¤Ê¤¤¤è¤¦¤Ë¤·¤Þ¤·¤ç¤¦¡×

¡Ö̤¾µÇ§°åÌôÉʤˤĤ¤¤ÆÍ¢ÆþÂå¹Ô¶È¼Ô¤òÍøÍѤ¹¤ë¤³¤È¼«ÂΤ¬Ä¾¤Á¤ËÌäÂê¤Ë¤Ï¤Ê¤ê¤Þ¤»¤ó¤¬¡¢Í¢ÆþÂå¹Ô¶È¼Ô¤ÎÃæ¤Ë¤ÏÌôµ¡Ë¡¤Ë°ãÈ¿¤·¤¿·Á¤Ç±Ä¶È¤ò¤ª¤³¤Ê¤¦°­¼Á¤Ê»ö¶È¼Ô¤â¸ºß¤·¤Þ¤¹¡£¤½¤Î¤è¤¦¤Ê»ö¶È¼Ô¤ËÍ¢ÆþÂå¹Ô¶È̳¤ò°ÑÂ÷¤·¤¿¾ì¹ç¡¢¥È¥é¥Ö¥ë¤Ë´¬¤­¹þ¤Þ¤ì¤ë²ÄǽÀ­¤Ï¤¢¤ê¤Þ¤¹¡£

¡¡

°ãË¡¤Ê̤¾µÇ§°åÌôÉʤÎÍ¢ÆþÂå¹Ô¶È¤È¤·¤Æ¤Ï¡¢¹­¹ð¤Ë¤è¤Ã¤ÆÉÔÆÃÄê¿¿ô¤Î¼Ô¤Î´õ˾¤òÊç¤Ã¤¿¤ê¡¢Êç¤Ã¤¿¾å¤Ç¾¦ÉʤȤʤë̤¾µÇ§°åÌôÉʤò°ì³çȯÁ÷¤Ë¤è¤Ã¤Æ»ö¶È¼Ô¤¬Ä¾ÀÜÍ¢Æþ¤ò¼õ¤±¡¢¸Ä¿Í¤ËÂФ·¤Æ¾¦ÉʤòȯÁ÷¡ÊÈÎÇä¡Ë¤¹¤ë¤è¤¦¤Ê¤â¤Î¤¬¤¢¤ê¤Þ¤¹¡£Ì¤¾µÇ§°åÌôÉʤˤĤ¤¤Æ¤ÏÈó¾ï¤Ë¸·¤·¤¤Ìôµ¡Ë¡¾å¤Î¹­¹ðµ¬À©¤¬¤¢¤ê¤Þ¤¹¤Î¤Ç¡¢¿··¿¥³¥í¥ÊÂкö¤Ç¥¤¥Ù¥ë¥á¥¯¥Á¥ó¤ÎÍ¢Æþ¤òÊç¤ë¤è¤¦¤Ê¹­¹ð¤Ï¤ä¤Ã¤Æ¤Ï¤¤¤±¤Ê¤¤¤â¤Î¤È¤ª¹Í¤¨²¼¤µ¤¤¡£

¡¡

¤Þ¤¿¡¢¾¦ÉʤÎȯÁ÷¤òľÀܳ°¹ñ¤Î»ö¶È¼Ô¤«¤é¸Ä¿Í¤ËÂФ·¤Æ¼è¼¡¤ò¤»¤º¡¢°ìö»ö¶È¼Ô¤¬Í¢Æþ¤ò¤·¤¿¸å¤Ë¸Ä¿Í¤ØÈ¯Á÷¤ò¤·¤Æ¤·¤Þ¤¦¤È¡¢Í¢Æþ¤ÎÂå¹Ô¤Ç¤Ï¤Ê¤¯Ì¤¾µÇ§°åÌôÉʤÎÈÎÇä¹Ô°Ù¤ÈȽÃǤµ¤ì¤ë¤¿¤á¡¢¤³¤ì¤â¤ä¤Ã¤Æ¤Ï¤¤¤±¤Ê¤¤¤â¤Î¤È¤ª¹Í¤¨²¼¤µ¤¤¡Ê¤¢¤¯¤Þ¤ÇÍ¢ÆþÂå¹Ô»ö¶È¼Ô¤¬¤Ç¤­¤ë¤Î¤ÏÍ¢Æþ¤Î¡ÖÂå¹Ô¡×¤Ç¤¹¡Ë¡×

ÆüËܰʾå¤ËÈ¿¥ï¥¯¥Á¥óÀªÎϤζ¯¤¤¥¢¥á¥ê¥«¤Ç¤Ï¥¤¥Ù¥ë¥á¥¯¥Á¥ó¤¬Âç¿Íµ¤¤È¤Ê¤ê¡¢¤¹¤´¤¤¤³¤È¤Ë¤Ê¤Ã¤Æ¤¤¤ëÍͻҡ£

ÊÆ¥ª¥¯¥é¥Û¥Þ½£¹Ù³°¤Î¤¢¤ë°å»Õ¤Ë¤è¤ì¤Ð¡¢ÇÏÍѤδóÀ¸Ãî¶î½üÌô¤Ë»È¤ï¤ì¤ë¥¤¥Ù¥ë¥á¥¯¥Á¥ó¤ò¿··¿¥³¥í¥Ê¥¦¥¤¥ë¥¹´¶À÷¾É¤Î¼£ÎÅÌô¤È¤·¤Æ²á¾êÀݼ褷¤¿¿Í¡¹¤¬¡¢Ãϸµ¤Îɱ¡¤ÎµßµÞ½èÃÖ¼¼¤òËä¤á¿Ô¤¯¤·¤Æ¤¤¤ë¤È¤¤¤¦¡£

¡¡

Ʊ½£ÅìÉô¤ÈÆîÉô¤ÎÊ£¿ô¤ÎµßµÞ½èÃÖ¼¼¤Ë¶Ð̳¤·¤Æ¤¤¤ë¥¸¥§¥¤¥½¥ó¡¦¥Þ¥¯¥¨¥ê¥¨°å»Õ¤Ï¡¢Ãϸµ¥Æ¥ì¥Ó¶ÉKFOR-TV¤ËÂФ·¤Æ¡¢¡Ö¤³¤ÎÌô¤ÎÉþÍѤˤ¢¤¿¤Ã¤Æ°å»Õ¤Î½èÊý¤¬É¬ÍפʤΤˤÏÍýͳ¤¬¤¢¤ë¡£¾ì¹ç¤Ë¤è¤Ã¤Æ¤Ï´í¸±¤À¤«¤é¤À¡×¤È½Ò¤Ù¤¿¡£

ÊÆ¼ÀÉÂÂкö¥»¥ó¥¿¡¼¡ÊCDC¡Ë¤ÏºÇ¶á¤ÎÀ¼ÌÀ¤Ç¡¢¡ÖÌô¶É¤ä¾®ÇäŹ¤Ç¥¤¥Ù¥ë¥á¥¯¥Á¥ó¤Î¼è¤ê°·¤¤Î̤¬Áý¤¨¤Æ¤¤¤ë¤¬¡¢¿Í´ÖÍѤËÈÎÇ䤵¤ì¤Æ¤¤¤ë¤â¤Î¤Ç¤Ï¤Ê¤¤¡×¤ÈÀâÌÀ¤·¤¿¡£

¡¡

CDC¤ÏÀ¼ÌÀ¤ÎÃæ¤Ç¤µ¤é¤Ë¡¢¡ÖFDA¤Ï¿··¿¥³¥í¥Ê´¶À÷¾É¤ÎͽËÉÌô¤Þ¤¿¤Ï¼£ÎÅÌô¤È¤·¤Æ¡¢¥¤¥Ù¥ë¥á¥¯¥Á¥ó¤Î»ÈÍѤòǧ²Ä¤â¾µÇ§¤â¤·¤Æ¤¤¤Ê¤¤¡×¤È½Ò¤Ù¤¿¡£¡ÖÊÆ¹ñΩ±ÒÀ¸¸¦µæ½ê¡ÊNIH¡Ë¤Î¿··¿¥³¥í¥Ê´¶À÷¾É¼£ÎÅ¥¬¥¤¥É¥é¥¤¥ó°Ñ°÷²ñ¤â¡¢¸½Ãʳ¬¤Ç¡¢¿··¿¥³¥í¥Ê´¶À÷¾É¤Î¼£ÎÅÌô¤È¤·¤Æ¥¤¥Ù¥ë¥á¥¯¥Á¥ó¤ò¿ä¾©¤¹¤ë½½Ê¬¤Ê¥Ç¡¼¥¿¤Ï¤Ê¤¤¤ÈȽÃǤ·¤Æ¤¤¤ë¡×

ÊÆ¹ñ°å»Õ²ñ¡ÊAMA¡Ë¡¢Á´ÊÆÌôºÞ»Õ¶¨²ñ¡ÊAPhA¡Ë¤ÈÁ´ÊÆÌôºÞ»Õ·ò¹¯¶¨²ñ¡ÊASHP¡Ë¤Ï¡¢9·î1Æü¤Ë¶¦Æ±¤ÇÀ¼ÌÀ¤òȯɽ¤·¤¿¡£

¡¡

¡Ö¥¤¥Ù¥ë¥á¥¯¥Á¥ó¤Î½èÊý¡¦ÈÎÇäÎ̤¬¥Ñ¥ó¥Ç¥ß¥Ã¥¯Á°¤ËÈæ¤Ù¤Æ24ÇܤËÁý¤¨¤Æ¤ª¤ê¡¢²áµî¿ô¥«·î¤ÇµÞÁý¤·¤Æ¤¤¤ë¤È¤¤¤¦ÊóÆ»¤Ë¡¢´íµ¡´¶¤òÊç¤é¤»¤Æ¤¤¤ë¡×¡Ö²æ¡¹¤È¤·¤Æ¤Ï¡¢Î×¾²»î¸³°Ê³°¤Ç¡¢¿··¿¥³¥í¥Ê´¶À÷¾É¤ÎͽËɤª¤è¤Ó¼£ÎÅÌô¤È¤·¤Æ¥¤¥Ù¥ë¥á¥¯¥Á¥ó¤ò½èÊý¡¢ÈÎÇ䤪¤è¤Ó»ÈÍѤ¹¤ë¤³¤È¤ò¡¢Â¨ºÂ¤Ë¤ä¤á¤ë¤è¤¦µá¤á¤ë¡×

¡¡

FDA¤Ï¤³¤ÎÌäÂê¤Ë¤Ä¤¤¤Æ¡¢¿Æ¤·¤ß¤ä¤¹¤¤¥á¥Ã¥»¡¼¥¸¤òȯ¿®¤·¤è¤¦¤È¡¢8·î¤Ë¥Ä¥¤¥Ã¥¿¡¼¤Ë¼¡¤Î¤è¤¦¤ËÅê¹Æ¤·¤¿¡£¡Ö¤¢¤Ê¤¿¤ÏÇϤǤϤ¢¤ê¤Þ¤»¤ó¡£µí¤Ç¤â¤¢¤ê¤Þ¤»¤ó¡£¤³¤ì¤Ï¿¿ÌÌÌܤÊÏäǤ¹¡£¤ä¤á¤Æ¤¯¤À¤µ¤¤¡×

ÅÄÊ¥ÀµÊ¸»á

½°±¡ÁªÅìµþ5¶è¤ËÆüËܰݿ·¤Î²ñ¤«¤éΩ¸õÊ䤷¤Æ¤¤¤ë°å»Õ¤ÎÅÄÊ¥ÀµÊ¸»á¡Ê63¡Ë¤Ï28Æü¡¢¿··¿¥³¥í¥Ê¤Ë´¶À÷¤·¤¿¤³¤È¤ò¼«¿È¤Î¥Õ¥§¥¤¥¹¥Ö¥Ã¥¯¤ÇÌÀ¤é¤«¤Ë¤·¤¿¡£¸ø¼¨¸å¤Ë¸õÊä¼Ô¤Î´¶À÷¤¬È½ÌÀ¤·¤¿¤Î¤Ï½é¤á¤Æ¤È¤ß¤é¤ì¤ë¡£¸½ºß¤ÏÆþ±¡Ãæ¤È¤¤¤¤¡¢¼èºà¤Ë¥á¡¼¥ë¤Ç¡Ö»ö̳½êÆâ¡Ê¤Î¥¹¥¿¥Ã¥Õ¡Ë¤Ë5¡¢6¿Í¤Î¥¯¥é¥¹¥¿¡¼¡Ê´¶À÷¼Ô½¸Ãġˤ¬È¯À¸¤·¤¿¡×¤È²óÅú¤·¤¿¡£

¡Ö¥¤¥Ù¥ë¥á¥¯¥Á¥ó+¥«¥â¥¹¥¿¥Ã¥È+¥¯¥é¥ê¥¹¥í¥Þ¥¤¥·¥ó»°¼ïÇÛ¹çºÞ¡×¤È¤¤¤¦¤â¤Î¤¬¿··¿¥³¥í¥Ê¤ÎÆÃ¸úÌô¤Ë¤Ê¤ë¤È¼çÄ¥¤¹¤ëÅÄÊ¥ÀµÊ¸¤Ê¤ë¿Íʪ¤¬°Ý¿·¤«¤éΩ¸õÊ䤷¡¢¤½¤Îľ¸å¡¢Áªµó»ö̳½êÆâ¤Ç¿··¿¥³¥í¥Ê¤Î¥¯¥é¥¹¥¿¡¼¤¬È¯À¸¤·¤¿¤È¤¤¤¦Ïá£